Effect of butyrate and Lactobacillus GG on a butyrate receptor and transporter during Campylobacter jejuni exposure

Gail A.M. Cresci, Paul C. Mayor, Stuart A. Thompson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Campylobacter jejuni frequently infects humans causing many gastrointestinal symptoms, fever, fatigue and several long-term debilitating diseases. Current treatment for campylobacteriosis includes rehydration and in some cases, antibiotic therapy. Probiotics are used to treat several gastrointestinal diseases. Butyrate is a short-chain fatty acid known to promote intestinal health. Interaction of butyrate with its respective receptor (HCAR2) and transporter (SLC5A8), both expressed in the intestine, is associated with water and electrolyte absorption as well as providing defense against colon cancer and inflammation. Alterations in gut microbiota influence the presence of HCAR2 and SLC5A8 in the intestine. We hypothesized that adherence and/or invasion of C. Jejuni and alterations in HCAR2 and SLC5A8 expression would be minimized with butyrate or Lactobacillus GG (LGG) pretreatment of Caco-2 cells. We found that both C. Jejuni adhesion but not invasion was reduced with butyrate pretreatment. While LGG pretreatment did not prevent C. Jejuni adhesion, it did result in reduced invasion which was associated with altered cell supernate pH. Both butyrate and LGG protected HCAR2 and SLC5A8 protein expression following C. Jejuni infection. These results suggest that the first stages of C. Jejuni infection of Caco-2 cells may be minimized by LGG and butyrate pretreatment.

Original languageEnglish (US)
Article numberfnx046
JournalFEMS Microbiology Letters
Volume364
Issue number6
DOIs
StatePublished - Mar 1 2017

Fingerprint

Lactobacillus rhamnosus
Campylobacter jejuni
Butyrates
Caco-2 Cells
Intestines
Volatile Fatty Acids
Gastrointestinal Diseases
Fluid Therapy
Probiotics
Infection
Colonic Neoplasms
Electrolytes
Fatigue
Fever
Anti-Bacterial Agents
Inflammation
Water
Health
Therapeutics

Keywords

  • Butyrate
  • Caco-2
  • Campylobacter jejuni
  • Lactobacillus GG

ASJC Scopus subject areas

  • Microbiology
  • Molecular Biology
  • Genetics

Cite this

Effect of butyrate and Lactobacillus GG on a butyrate receptor and transporter during Campylobacter jejuni exposure. / Cresci, Gail A.M.; Mayor, Paul C.; Thompson, Stuart A.

In: FEMS Microbiology Letters, Vol. 364, No. 6, fnx046, 01.03.2017.

Research output: Contribution to journalArticle

@article{808340c1da054d32b14afcb51bc89bb3,
title = "Effect of butyrate and Lactobacillus GG on a butyrate receptor and transporter during Campylobacter jejuni exposure",
abstract = "Campylobacter jejuni frequently infects humans causing many gastrointestinal symptoms, fever, fatigue and several long-term debilitating diseases. Current treatment for campylobacteriosis includes rehydration and in some cases, antibiotic therapy. Probiotics are used to treat several gastrointestinal diseases. Butyrate is a short-chain fatty acid known to promote intestinal health. Interaction of butyrate with its respective receptor (HCAR2) and transporter (SLC5A8), both expressed in the intestine, is associated with water and electrolyte absorption as well as providing defense against colon cancer and inflammation. Alterations in gut microbiota influence the presence of HCAR2 and SLC5A8 in the intestine. We hypothesized that adherence and/or invasion of C. Jejuni and alterations in HCAR2 and SLC5A8 expression would be minimized with butyrate or Lactobacillus GG (LGG) pretreatment of Caco-2 cells. We found that both C. Jejuni adhesion but not invasion was reduced with butyrate pretreatment. While LGG pretreatment did not prevent C. Jejuni adhesion, it did result in reduced invasion which was associated with altered cell supernate pH. Both butyrate and LGG protected HCAR2 and SLC5A8 protein expression following C. Jejuni infection. These results suggest that the first stages of C. Jejuni infection of Caco-2 cells may be minimized by LGG and butyrate pretreatment.",
keywords = "Butyrate, Caco-2, Campylobacter jejuni, Lactobacillus GG",
author = "Cresci, {Gail A.M.} and Mayor, {Paul C.} and Thompson, {Stuart A.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1093/femsle/fnx046",
language = "English (US)",
volume = "364",
journal = "FEMS Microbiology Letters",
issn = "0378-1097",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Effect of butyrate and Lactobacillus GG on a butyrate receptor and transporter during Campylobacter jejuni exposure

AU - Cresci, Gail A.M.

AU - Mayor, Paul C.

AU - Thompson, Stuart A.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Campylobacter jejuni frequently infects humans causing many gastrointestinal symptoms, fever, fatigue and several long-term debilitating diseases. Current treatment for campylobacteriosis includes rehydration and in some cases, antibiotic therapy. Probiotics are used to treat several gastrointestinal diseases. Butyrate is a short-chain fatty acid known to promote intestinal health. Interaction of butyrate with its respective receptor (HCAR2) and transporter (SLC5A8), both expressed in the intestine, is associated with water and electrolyte absorption as well as providing defense against colon cancer and inflammation. Alterations in gut microbiota influence the presence of HCAR2 and SLC5A8 in the intestine. We hypothesized that adherence and/or invasion of C. Jejuni and alterations in HCAR2 and SLC5A8 expression would be minimized with butyrate or Lactobacillus GG (LGG) pretreatment of Caco-2 cells. We found that both C. Jejuni adhesion but not invasion was reduced with butyrate pretreatment. While LGG pretreatment did not prevent C. Jejuni adhesion, it did result in reduced invasion which was associated with altered cell supernate pH. Both butyrate and LGG protected HCAR2 and SLC5A8 protein expression following C. Jejuni infection. These results suggest that the first stages of C. Jejuni infection of Caco-2 cells may be minimized by LGG and butyrate pretreatment.

AB - Campylobacter jejuni frequently infects humans causing many gastrointestinal symptoms, fever, fatigue and several long-term debilitating diseases. Current treatment for campylobacteriosis includes rehydration and in some cases, antibiotic therapy. Probiotics are used to treat several gastrointestinal diseases. Butyrate is a short-chain fatty acid known to promote intestinal health. Interaction of butyrate with its respective receptor (HCAR2) and transporter (SLC5A8), both expressed in the intestine, is associated with water and electrolyte absorption as well as providing defense against colon cancer and inflammation. Alterations in gut microbiota influence the presence of HCAR2 and SLC5A8 in the intestine. We hypothesized that adherence and/or invasion of C. Jejuni and alterations in HCAR2 and SLC5A8 expression would be minimized with butyrate or Lactobacillus GG (LGG) pretreatment of Caco-2 cells. We found that both C. Jejuni adhesion but not invasion was reduced with butyrate pretreatment. While LGG pretreatment did not prevent C. Jejuni adhesion, it did result in reduced invasion which was associated with altered cell supernate pH. Both butyrate and LGG protected HCAR2 and SLC5A8 protein expression following C. Jejuni infection. These results suggest that the first stages of C. Jejuni infection of Caco-2 cells may be minimized by LGG and butyrate pretreatment.

KW - Butyrate

KW - Caco-2

KW - Campylobacter jejuni

KW - Lactobacillus GG

UR - http://www.scopus.com/inward/record.url?scp=85019909727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019909727&partnerID=8YFLogxK

U2 - 10.1093/femsle/fnx046

DO - 10.1093/femsle/fnx046

M3 - Article

C2 - 28333199

AN - SCOPUS:85019909727

VL - 364

JO - FEMS Microbiology Letters

JF - FEMS Microbiology Letters

SN - 0378-1097

IS - 6

M1 - fnx046

ER -